达维塔保健今日盘中大幅上涨17.18%，引起了市场的广泛关注。
消息面上，公司发布了远超市场预期的2026年年度利润预测，其给出的调整后每股收益指引区间为13.60美元至15美元，显著高于分析师平均预期的12.65美元。公司将这一乐观展望归因于对其核心肾透析服务的稳定需求。此外，公司公布的第四季度调整后每股收益为3.40美元，也超过了市场预期，利润的提升得益于报销率提高、流感疫苗组合改善以及季节性因素的积极影响。
与此同时，公司宣布将与临终关怀服务提供商Elara合作，共同开发一种专门针对肾脏疾病的家庭护理模式，旨在减少可预防的住院治疗并改善患者治疗效果。这一战略举措进一步增强了投资者对公司未来增长潜力的信心。知名投行巴克莱也因此将公司的目标股价从143美元上调至158美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.